Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

Fig. 3

PARPi suppress the clonogenic ability of BLCA cells in vitro. A The BLCA cell lines UM-UC-3 and T-24 and the normal urothelial cells SV-HUC-1 were treated with sub-IC50 concentrations of niraparib, olaparib, rucaparib (5 μM each), talazoparib (0.5 μM) either singly or in combination with sub-IC50 concentration of cisplatin (0.5 μM) for 72 h. Cells were plated at low densities (400 cells/well) in 6-well plates and incubated at 37oC in a 5% CO2-incubator for 10-14 days. At the end of the experiment, colonies were stained with 0.5% crystal violet in buffered formalin and counted using the Colony Counter plug-in of ImageJ. Results are presented as means±SD of 3 independent experiments with triplicates. P ≤ 0.05 was considered significant (*). B Representative images of colonies formed by SV-HUC-1, UM-UC-3, and T-24 cells after treatment

Back to article page